Clinical Trials · NCT03017690

Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Name: Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedN/AOctreotide Lanreotide

Phase: N/A
Recruitment status: Completed
Sponsor: Ipsen
Enrollment: 22
Start date: Apr 2017
Locations: 5 sites, United States
Primary endpoint: The total time for product preparation and administration

View Octreotide compound reference